he New Company shall develop a trading platform to assist pharmaceutical products from the PRC to enter into the markets in the USA, Canada and the European Union; involve in the drug quality standards and the third-party arbitration services; provide training on FDA related services and standards for Chinese drug manufacturing enterprises; provide services of FDA application and advices for Chinese drug manufacturing enterprises; and establish branch offices in major pharmaceutical regional centres in the PRC, to expand its market share.